Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY2 | Q08462 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568267 | 0.87 | HTT (0.39) | ADCY2CCR1FFAR1HTTTP53 | |
| SCHEMBL6524338 | 0.83 | MAPT (0.38) | ADCY2CCR1FFAR1HTTTP53 | |
| SCHEMBL5568264 | 0.81 | ADRA1D (0.39) | ADCY2CCR1FFAR1HTTTP53 | |
| SCHEMBL5562887 | 0.78 | HTT (0.43) | HTTMAPTCACNA1BADRA1DADRA1A | |
| SCHEMBL5568028 | 0.74 | HTT (0.40) | HTTCACNA1BADRA1DADRA1AADRA1B | |
| SCHEMBL5567175 | 0.73 | HTT (0.40) | CCR1HTTMAPTCACNA1BADRA1D | |
| SCHEMBL5564795 | 0.73 | HTT (0.41) | HTTCACNA1BUSP2ADRA1DADRA1A | |
| SCHEMBL5563519 | 0.73 | MAPT (0.41) | CCR1HTTMAPTTSHRLMNA | |
| SCHEMBL5567824 | 0.73 | HTT (0.39) | HTTMAPTCACNA1BADRA1DADRA1A | |
| SCHEMBL5563145 | 0.73 | CACNA1B (0.43) | HTTTP53MAPTTSHRCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | CACNA1E, CACNA1C, CACNA1S | ADCY2 712/4885CCR1 3435/4885FFAR1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.